When asked by Sen. Tammy Baldwin, D-Wis., who was specifically responsible for the grant terminations and delays at the NIH, ...

With billions of dollars of federal research funding cut since President Donald Trump began his second term, organizations ...

Cancer clinical trial specialist Sarah Cannon Research Institute is unifying its site management and contract research ...

Quest Diagnostics will work on a blood test for cancer risk that it says may help identify people who could benefit from more ...

Pfizer CEO Albert Bourla has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing that his ...

The spinout, dubbed Antares Therapeutics, will be fueled by a $177 million series A round co-led by Omega Funds, Atlas ...

Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of ...

Medtronic has named a new head of its acute care and monitoring division, tapping Kate Benedict to help lead the company’s ...

Keros Therapeutics’ pledge to hand $375 million to shareholders has not been enough to appease activist investor demands to ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...